ISSN: 1859 - 2872
Functional and anatomical results of intravitreal ranibizumab injection cours of wet age-related macular degeneration treatment
Main Article Content
Keywords
Abstract
Summary
Objective: To evaluate functional and anatomical results of intravitreal ranibizumab injection cours of wet age-related macular degeneration treatment over a 12-month observation period. Subject and method: 23 eyes in 22 patients with wet age-related macular degeneration treatment was performed according to the following schedules: 3 intravitreal injections of 0.5mg ranibizumab at monthly intevals (saturation phase). Further injection was based on the activity of neovascular process. Result: Mean pre-treatment best corrected visual acuity was 0.09. After the third ranibizumab injection the best results, 0.22 were seen, 12-month results were 0.21. Baseline mean central retinal thickness was 435µ. After the third injection was 358µ. After 12 months it was 358µ. The mean number of injections in the 12-month period was 3.7. Conclusion: Treatment intravitreal ranibizumab injection according to presented scheme provides wet age-related macular degeneration patients with a chance of stabilization and improvement of topical state, with a lower number injection and preserved topical and general safety. Regular monthly control in necessary to be able react rapidly to smallest signal deterioration, not only in visual acuity, but also OCT images.
Keywords: Age-related macular denegenation, ranibizumab.
Article Details
References
2. Brown DM et al (2006) The Anchor study group: ranibizumab versus verteporfin for neovascular age-related macular denegenation. N Engl J Med 355: 1432-1444.
3. Fung AF Lalwani GA, Rosenfiel (2007) An optical coherence tomography- guided, variable dosing regime with intravitreal ranibizumab for neovascular age-related macular degeneration. Am J Ophthalmol 143: 566-583.
4. Geeta A et al (2009) A variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-Related macular degeneration: The pronto study. Am J Ophthalmol 148: 43-58.
5. Kiss ChG, Geizenauer W et al (2009) Evaluation of ranibizumab - induced changes in high- resolution optical coherence tomographic retinal morphology and their inpact on visual function. Investigative Ophthamology and Visual Science 50: 2376-2383.
6. Lawani GA, Rosenfeld PJ, Fung AF et al (2009) A veriable - dosing regimen with intravitreal ranibizumab for neovascular age-related macular denegenation: The PrONTO study. Am J Ophthalmol 148: 43-53.
7. Malgorzata Figurska et al (2011) Effectiveness of ranibizumab intravitreal injections for exudative age-related macular degeneration treatment: 12 month outcomes. Med Sci Monit 17(9): 485-490.
8. Michell P et al (2010) Ranibizumab (Lucentis) in neovascular age-related macular denegenation: evidence from clinical trials. Br J Opthalmol 94: 2-13.
9. Rober L, Johston et al (2010) A retrospestive study of ranibizumab treatment regimes for neovascular age – related macular denegenation in Australis and United Kingdom. Br J Opthalmol 74: 12-19.
Article Sidebar
